ADC Development for Renal Cancer

The development of Antibody-Drug Conjugates (ADCs) for renal cancer represents a promising approach in the treatment of this challenging malignancy. Renal cancer, particularly renal cell carcinoma (RCC), often exhibits resistance to conventional therapies, making innovative treatments crucial for improving patient…